JP2004231544A - Utilization of phospholipid as melamine production inhibitor - Google Patents

Utilization of phospholipid as melamine production inhibitor Download PDF

Info

Publication number
JP2004231544A
JP2004231544A JP2003020321A JP2003020321A JP2004231544A JP 2004231544 A JP2004231544 A JP 2004231544A JP 2003020321 A JP2003020321 A JP 2003020321A JP 2003020321 A JP2003020321 A JP 2003020321A JP 2004231544 A JP2004231544 A JP 2004231544A
Authority
JP
Japan
Prior art keywords
phospholipid
hydrogenated
production inhibitor
phase component
cosmetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003020321A
Other languages
Japanese (ja)
Inventor
Megumi Obayashi
恵 大林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmos Technical Center Co Ltd
Nikko Chemicals Co Ltd
Original Assignee
Cosmos Technical Center Co Ltd
Nikko Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmos Technical Center Co Ltd, Nikko Chemicals Co Ltd filed Critical Cosmos Technical Center Co Ltd
Priority to JP2003020321A priority Critical patent/JP2004231544A/en
Publication of JP2004231544A publication Critical patent/JP2004231544A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a melamine production inhibitor which has excellent safety and a mild action and is suitable for cosmetics and skin care preparations for external use. <P>SOLUTION: This melamine production inhibitor contains a phospholipid and/or a hydrogenated phospholipid as essential ingredients. Herein, the phospholipid and/or the hydrogenated phospholipid are preferably glycerophospholipid, sphingophospholipid. Concretely, the phospholipid is phosphatidylcholine or phosphatidylethanolamine, and their hydrogenated products are phosphatidylcholine, hydrogenated phosphatidylethanolamine, especially hydrogenated soybean phospholipid. <P>COPYRIGHT: (C)2004,JPO&NCIPI

Description

【0001】
【発明が属する技術分野】
本発明は安全性に優れ、かつ作用が穏やかであるメラニン生成抑制剤に関するものであり、従来からの美白成分の安全性、及び安定性を改善したメラニン生成抑制剤に関する。
【0002】
【従来の技術】
従来から化粧品、医薬部外品に用いられる美白成分としては、いわゆる化学合成系の成分としてはアスコルビン酸、アルブチン、エラグ酸、コウジ酸、ルシノール、グルタチオン、リノール酸、リノレン酸、乳酸、トラネキサム酸、ビフェニル化合物、パンテテイン−S−スルホン酸カルシウム、イオウ、またこれらの誘導体が、また天然物由来の成分としてはプラセンタエキス、油溶性甘草エキス(グラブリジン)、ラズベリーケトングルコシド、ウワウルシエキス、甘草エキス、アセロラエキス、アルモンドエキス、アロエエキス、イチョウエキス、イブキトラノオエキス、エイジツエキス等の動植物抽出物が用いられてきた。
【0003】
しかしながら、合成系の美白成分ではアスコルビン酸及びその誘導体を除いて皮膚刺激性や安全性が指摘される場合もあり、また癌原性が問題となる場合もある。また天然物由来の美白成分では、一般的には皮膚刺激性や安全性には問題は無いとされるが、皮膚刺激性や安全性に問題を生じる場合もあり、また安定性には問題が多い。
【0004】
【発明が解決しようとする課題】
このように、美白成分は化粧品や医薬部外品においては必須の成分であるが、美白効果と安全性を兼ね備える成分は無かった。
本発明の課題は、安全性に優れかつ作用が穏やかなメラニン生成抑制剤を見出すことである。
【0005】
【課題を解決するための手段】
本発明者は、安全性に優れかつ作用が穏やかであるメラニン生成抑制剤を見出すべく鋭意研究した結果、リン脂質がメラニン生成抑制作用を示すことを見出した。リン脂質は本質的に天然物由来であり安全性に優れること、また両親媒性物質であることから化粧品や医薬部外品に配合しやすいこと、また更に安定性に優れることから穏やかな美白作用を持つ成分であることを確認するに至り、本発明を完成した。
【0006】
すなわち本発明は、以下の構成により実現される。
(1)リン脂質、及び/又はリン脂質の水素添加物を必須成分とするメラニン生成抑制剤。
(2)リン脂質、及び/又はリン脂質の水素添加物が、グリセロリン脂質、スフィンゴリン脂質である(1)に記載のメラニン生成抑制剤。
(3)リン脂質が、水素添加大豆リン脂質である(1)に記載のメラニン生成抑制剤。
(4)、(1)〜(3)に記載のリン脂質をメラニン生成抑制剤として用いる化粧料、及び皮膚外用剤。
【0007】
【発明の実施の形態】
本発明で用いるリン脂質は特に制限されることは無く、グリセロリン脂質、スフィンゴリン脂質等を用いることが出来る。
【0008】
グリセロリン脂質としてはホスファチド酸、ホスファチジルセリン、ホスファチジルエタノールアミン、ホスファチジル−N−メチルエタノールアミン、ホスファチジル−N,N−ジメチルエタノールアミン、ホスファチジルコリン、ホスファチジルグリセロール、ホスファチジル−O−アミノアシルグリセロール、ホスファチジルグリセロリン酸、ジホスファチジルグリセロール、ホスファチジルイノシトール、ホスファチジルイノシトール一リン酸、ホスファチジルイノシトール二リン酸、リゾホスファチジルコリン、リゾホスファチジルエタノールアミン等の例を挙げることが出来る。
【0009】
スフィンゴリン脂質としてはグリセロホスホノ脂質、エーテルグリセロリン脂質、セラミド−1−リン酸の誘導体であるセラミドリン酸、スフンゴミエリン、セラミドホスホリルエタノールアミン、セラミドホスホリルグリセロール等の例を挙げることが出来る。
【0010】
またこれらのリン脂質を含有する、大豆由来であるいわゆる大豆リン脂質(大豆レシチン)、卵黄由来であるいわゆる卵黄リン脂質(卵黄レシチン)等を好適に用いることができる。またこれらの水素添加物も好適に用いることができる。
【0011】
本発明で用いるリン脂質の添加量は0.01重量%〜60重量%であるが、好ましくは0.1重量%〜30重量%である。これ以上添加量を増加させても効果の増大は見られず、またこれ以下の添加量では効果が見られない。
【0012】
本発明で用いるリン脂質に加えて、アスコルビン酸、アルブチン、エラグ酸、コウジ酸、及びプラセンタエキス、油溶性甘草エキス、ラズベリーケトングルコシド等の一般的に用いられるメラニン生成抑制剤を併用することは美白効果の相乗効果をもたらし、本発明の効果を損なうものではない。
【0013】
本発明の化粧料、及び皮膚外用剤には、上記必須成分のほか本発明の効果を損なわない範囲で化粧品、医薬部外品などの皮膚外用剤に配合される成分として動植物油由来の硬化油、天然由来のロウ、炭化水素系の油相成分、動植物由来の油相成分、シリコーン系の油相成分、フッ素系の油相成分、高級アルコール、増粘剤、紫外線吸収剤、粉体、顔料、陰イオン性界面活性剤、陽イオン性界面活性剤、非イオン性界面活性剤、多価アルコール、糖、高分子化合物、生理活性成分、経皮吸収促進剤、溶媒、酸化防止剤、香料、防腐剤等を配合することができる。
【0014】
本発明の化粧料としては、例えばファンデーション、白粉、アイシャドウ、アイライナー、アイブロー、チーク、口紅、ネイルカラー等のメイクアップ化粧料、乳液、クリーム、ローション、カラミンローション、サンスクリーン剤、サンタン剤、アフターシェープローション、プレシェープローション、パック料、アクネ対策化粧料、エッセンス等の基礎化粧料、シャンプー、リンス、コンディショナー、ヘアカラー、ヘアトニック、セット剤、養毛料、パーマネント剤等の頭髪化粧料、ボディパウダー、デオドラント、脱毛剤、セッケン、ボディシャンプー、入浴剤、ハンドソープ、香水等が挙げられる。
【0015】
【実施例】
以下に実施例を挙げて本発明を具体的に説明するが、本発明の技術的範囲がこれらに限定されるものではない。
【0016】
先ず、リン脂質のメラニン産生阻害作用を、B16メラノーマ細胞により評価した結果を示す。
用いたリン脂質は、グリセロリン脂質類における水素添加ホスファチジルコリンとして2,3−ジパルミトイル−sn−グリセロ−1−ホスホコリン(試薬:シグマ社)を、水素添加ホスファチジルエタノールアミンとして2,3−ジパルミトイル−sn−グリセロ−3−ホスホエタノールアミン(試薬:シグマ社)を、また工業製品として利用可能な、純度が85%以上である水素添加大豆リン脂質(1)(NIKKOL レシノールS−10 EX:日光ケミカルズ)を、同様に通常の水素添加大豆リン脂質(2)(NIKKOL レシノールS−10:日光ケミカルズ)を用いた。
また更に、スフィンゴリン脂質類としてスフィンゴミエリン(試薬:シグマ社)を用いた。
【0017】
(B16メラノーマ細胞のトータルメラニン産生阻害作用の評価)
B16マウス メラノーマF0株(B16F0)は2.0×10 cells/wellの細胞密度で6穴プレートに播種した。24時間D−MEM(Dulbecco‘s Modified Eagle Medium)にて培養後、試料含有培地に交換した。更に6日間培養後、細胞をPBS buffer(Dulbecco‘s Phosphate−Buffered Salines)にて洗浄後トリプシンにて細胞剥離し、細胞ペレットを作成した。続いてこの細胞ペレットにつきBCA法(BCA Protein Assay:detergent−compatible formation based onbicinchonic acid)による蛋白定量およびメラニン定量を行なった。すなわち、細胞ペレットを5%トリクロロ酢酸(3回)、エタノール/ジエチルエーテル(3/1:容積比)溶液(2回)、ジエチルエーテル(1回)にてそれぞれ洗浄および遠心(15×10rpm(1分)を繰り返した後、1N水酸化ナトリウム存在下にて加熱溶解(100℃、5分)した。マイクロプレートリーダーを用いて430nmの吸光度を測定し、ユウメラニン量を算出した。メラニンの検量線は、合成メラニン(シグマ社製)を標準品として作成した。ユウメラニン量を蛋白量で除した値を、蛋白量あたりのメラニン量とした。
【0018】
【表1】

Figure 2004231544
【0019】
【表2】
Figure 2004231544
表1、及び表2に見られるように、2,3−ジパルミトイル−sn−グリセロ−1−ホスホコリン、2,3−ジパルミトイル−sn−グリセロ−3−ホスホエタノールアミン、スフィンゴミエリン、水素添加大豆リン脂質(1)、水素添加大豆リン脂質(2)を添加することにより、明らかなメラニン量/蛋白質量の減少が見られ、リン脂質のメラニン生成抑制効果が分かる。
【0020】
次に、実際の皮膚外用剤及び化粧品処方に水素添加大豆リン脂質をメラニン生成抑制剤として用いた場合の美白効果の例を示す。
【0021】
実施例8:保湿クリーム
Figure 2004231544
(調製方法)
油相成分、水相成分ともに80℃で加温溶解し,水相成分を油相成分に撹拌しながら徐々に加え乳化する。撹拌しながら35℃〜40℃になるまで冷却する。
【0022】
実施例9:エモリエントクリーム
Figure 2004231544
(調製方法)
実施例8と同様の方法で調製した。
【0023】
実施例10:サンスクリーンクリーム
Figure 2004231544
(調製方法)油相成分、及び水相成分ともに70〜80°Cに加温し、均一に溶解する。水相成分を油相成分に加入し、80°Cに保ちながらホモミキサーで5000rpmで7分間撹拌後、パドル撹拌しながら30℃〜35℃まで冷却する。
【0024】
実施例11:乳液
Figure 2004231544
(調製方法)A相成分、及びB相成分ともに80°Cで加温溶解し,B相成分をA相成分にホモミキサーで撹拌しながら徐々に加え、5000rpmで5分間撹拌する。パドル撹拌しながら冷却し、約50°CでC相成分を添加し、攪拌しながら35℃〜40°Cまで冷却する。
【0025】
実施例12:化粧水
Figure 2004231544
(調製方法)
油相成分、水相成分もに50°Cで加温溶解し、油相成分を水相成分に撹拌しながら徐々に加えて可溶化する。撹拌しながら30℃まで冷却する。
【0026】
実施例13:美容液
Figure 2004231544
(調製方法)
A相成分〜D相成分を常温で溶解する。B相成分をA相成分に撹拌しながら徐々に加え粘稠性液体とし、ついでC相成分、D相成分を加え均一とする。
(美白効果の評価)
被験者(20〜40才台の女性、25名)の顔面に、実施例1〜6及び比較例1〜5の試作皮膚外用剤を朝夕の一日2回、3ヶ月間、毎日塗布した。1ヶ月後、2ヶ月後、3ヶ月後の美白効果を、目視判定で調べ、試験開始前後における色黒、しみ、そばかすの程度を4段階で評価した。
(評価基準)
1:色黒、しみ、そばかすの改善効果が顕著に確認された。
2:色黒、しみ、そばかすの改善効果が確認された。
3:色黒、しみ、そばかすの改善効果が若干確認された。
4:色黒、しみ、そばかすが改善効果が全く無かった。
(判定基準)
◎:80%以上の被験者に評価基準2以上の改善が見られた。
○:50%以上80%未満の被験者に評価基準2以上の改善が見られた。
△:30%以上50%未満の被験者に評価基準3程度の改善が見られた。
×:改善が見られなかった。
【0027】
【表3】
Figure 2004231544
表3に見られるように、水素添加大豆リン脂質は、美白効果は穏やかであるが、3ヶ月程度で顕著な美白効果が現れることが分かる。
【0028】
【発明の効果】
以上、詳細に説明したように、グリセロリン脂質、スフィンゴリン脂質等のリン脂質は穏やかな美白作用を持つ成分であり、また水素添加大豆リン脂質は安全性に優れ、両親媒性物質であることから化粧品等に利用しやすい優れた美白成分であることが分かる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a melanin production inhibitor excellent in safety and mild in action, and relates to a melanin production inhibitor having improved safety and stability of a conventional whitening component.
[0002]
[Prior art]
Conventionally, as a whitening ingredient used in cosmetics and quasi-drugs, as a so-called chemically synthesized ingredient, ascorbic acid, arbutin, ellagic acid, kojic acid, rucinol, glutathione, linoleic acid, linolenic acid, lactic acid, tranexamic acid, Biphenyl compounds, pantethein-S-calcium sulfonate, sulfur, and derivatives thereof, and components derived from natural products include a placenta extract, an oil-soluble licorice extract (grabridine), raspberry ketone glucoside, an awaurushi extract, a licorice extract, an acerola extract, Animal and plant extracts such as almond extract, aloe extract, ginkgo extract, Ibukitorano extract and Eijitsu extract have been used.
[0003]
However, skin irritation and safety may be pointed out in synthetic whitening components except for ascorbic acid and its derivatives, and carcinogenicity may become a problem. In addition, whitening ingredients derived from natural products are generally considered to have no problem with skin irritation and safety, but may cause problems with skin irritation and safety, and also have problems with stability. Many.
[0004]
[Problems to be solved by the invention]
As described above, the whitening component is an essential component in cosmetics and quasi-drugs, but there is no component having both a whitening effect and safety.
An object of the present invention is to find a melanin production inhibitor excellent in safety and mild in action.
[0005]
[Means for Solving the Problems]
The present inventors have conducted intensive studies to find a melanin production inhibitor having excellent safety and mild action, and as a result, have found that phospholipids exhibit a melanin production inhibitory effect. Phospholipids are derived from natural products and are excellent in safety. They are amphipathic substances, so they can be easily incorporated into cosmetics and quasi-drugs. It has been confirmed that the component has the above formula, and the present invention has been completed.
[0006]
That is, the present invention is realized by the following configurations.
(1) A melanin production inhibitor comprising a phospholipid and / or a hydrogenated phospholipid as an essential component.
(2) The melanogenesis inhibitor according to (1), wherein the phospholipid and / or the hydrogenated phospholipid are glycerophospholipids and sphingolipids.
(3) The melanin production inhibitor according to (1), wherein the phospholipid is hydrogenated soybean phospholipid.
(4) Cosmetics using the phospholipid according to (1) to (3) as a melanin production inhibitor, and an external preparation for skin.
[0007]
BEST MODE FOR CARRYING OUT THE INVENTION
The phospholipid used in the present invention is not particularly limited, and glycerophospholipid, sphingophospholipid and the like can be used.
[0008]
Examples of glycerophospholipids include phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidyl-N-methylethanolamine, phosphatidyl-N, N-dimethylethanolamine, phosphatidylcholine, phosphatidylglycerol, phosphatidyl-O-aminoacylglycerol, phosphatidylglycerophosphate, and diphosphatidyl. Examples include glycerol, phosphatidylinositol, phosphatidylinositol monophosphate, phosphatidylinositol diphosphate, lysophosphatidylcholine, and lysophosphatidylethanolamine.
[0009]
Examples of sphingolipids include glycerophosphonolipids, ether glycerophospholipids, ceramide-1-phosphate derivatives ceramide phosphoric acid, sphingomyelin, ceramide phosphorylethanolamine, and ceramide phosphoryl glycerol.
[0010]
Further, so-called soybean phospholipids (soybean lecithin) derived from soybean and so-called egg yolk phospholipids (egg yolk lecithin) containing these phospholipids can be preferably used. Also, these hydrogenated products can be suitably used.
[0011]
The addition amount of the phospholipid used in the present invention is 0.01% by weight to 60% by weight, preferably 0.1% by weight to 30% by weight. Even if the addition amount is further increased, the effect is not increased, and if the addition amount is less than this, no effect is observed.
[0012]
In addition to the phospholipids used in the present invention, ascorbic acid, arbutin, ellagic acid, kojic acid, and a commonly used melanin production inhibitor such as placenta extract, oil-soluble licorice extract, and raspberry ketone glucoside are effective in whitening. And does not impair the effects of the present invention.
[0013]
The cosmetics of the present invention and the external preparation for skin include hardened oils derived from animal and vegetable oils as components to be added to the external preparation for skin such as cosmetics and quasi-drugs in addition to the above essential components as long as the effects of the present invention are not impaired. , Natural wax, hydrocarbon oil phase component, animal and plant oil phase component, silicone oil phase component, fluorine oil phase component, higher alcohol, thickener, ultraviolet absorber, powder, pigment , Anionic surfactants, cationic surfactants, nonionic surfactants, polyhydric alcohols, sugars, polymer compounds, physiologically active ingredients, transdermal absorption enhancers, solvents, antioxidants, fragrances, Preservatives and the like can be added.
[0014]
Examples of the cosmetics of the present invention include foundation, white powder, eyeshadow, eyeliner, eyebrow, cheek, lipstick, nail color and other makeup cosmetics, emulsions, creams, lotions, calamine lotions, sunscreens, suntans, Basic cosmetics such as after-shave lotions, pre-shapes lotions, packs, anti-acne cosmetics, essences, etc., hair cosmetics such as shampoos, rinses, conditioners, hair colors, hair tonics, set preparations, hair restorations, permanents, etc., body Powders, deodorants, hair removers, soaps, body shampoos, bath additives, hand soaps, perfumes and the like can be mentioned.
[0015]
【Example】
Hereinafter, the present invention will be described specifically with reference to Examples, but the technical scope of the present invention is not limited thereto.
[0016]
First, the results of evaluating the melanin production inhibitory action of phospholipids using B16 melanoma cells are shown.
The phospholipids used were 2,3-dipalmitoyl-sn-glycero-1-phosphocholine (reagent: Sigma) as hydrogenated phosphatidylcholine in glycerophospholipids and 2,3-dipalmitoyl-sn as hydrogenated phosphatidylethanolamine. -Glycero-3-phosphoethanolamine (reagent: Sigma) and hydrogenated soybean phospholipid (1) (NIKKOL Resinol S-10 EX: Nikko Chemicals) having a purity of 85% or more and usable as an industrial product In the same manner, ordinary hydrogenated soybean phospholipid (2) (NIKKOL Resinol S-10: Nikko Chemicals) was used.
Further, sphingomyelin (reagent: Sigma) was used as sphingolipids.
[0017]
(Evaluation of total melanin production inhibitory action of B16 melanoma cells)
B16 mouse melanoma F0 strain (B16F0) was seeded on a 6-well plate at a cell density of 2.0 × 10 3 cells / well. After culturing for 24 hours in D-MEM (Dulbecco's Modified Eagle Medium), the medium was replaced with a sample-containing medium. After further culturing for 6 days, the cells were washed with PBS buffer (Dulbecco's Phosphate-Buffered Salines) and then detached with trypsin to prepare cell pellets. Subsequently, the cell pellet was subjected to protein quantification and melanin quantification by the BCA method (BCA Protein Assay: detergent-compatible formation based on bicinchonic acid). That is, the cell pellet is washed and centrifuged (15 × 10 3 rpm) with 5% trichloroacetic acid (3 times), an ethanol / diethyl ether (3/1: volume ratio) solution (2 times), and diethyl ether (1 time). After repeating (1 minute), the mixture was heated and dissolved in the presence of 1N sodium hydroxide (100 ° C., 5 minutes), and the absorbance at 430 nm was measured using a microplate reader to calculate the amount of melanin. A calibration curve was prepared using synthetic melanin (manufactured by Sigma) as a standard, and the value obtained by dividing the amount of melanin by the amount of protein was defined as the amount of melanin per amount of protein.
[0018]
[Table 1]
Figure 2004231544
[0019]
[Table 2]
Figure 2004231544
As seen in Tables 1 and 2, 2,3-dipalmitoyl-sn-glycero-1-phosphocholine, 2,3-dipalmitoyl-sn-glycero-3-phosphoethanolamine, sphingomyelin, hydrogenated soybean By adding the phospholipid (1) and the hydrogenated soybean phospholipid (2), a clear decrease in the amount of melanin / protein mass is seen, and the effect of the phospholipid on inhibiting the production of melanin is understood.
[0020]
Next, examples of the whitening effect when hydrogenated soybean phospholipid is used as a melanin production inhibitor in actual skin external preparations and cosmetic formulations are shown.
[0021]
Example 8: Moisturizing cream
Figure 2004231544
(Preparation method)
The oil phase component and the water phase component are both heated and dissolved at 80 ° C., and the water phase component is gradually added to the oil phase component with stirring to emulsify. Cool to 35 ° C to 40 ° C with stirring.
[0022]
Example 9: Emollient cream
Figure 2004231544
(Preparation method)
Prepared in the same manner as in Example 8.
[0023]
Example 10: Sunscreen cream
Figure 2004231544
(Preparation method) Both the oil phase component and the aqueous phase component are heated to 70 to 80 ° C. and uniformly dissolved. The aqueous phase component is added to the oil phase component, and the mixture is stirred at 5000 rpm for 7 minutes while maintaining the temperature at 80 ° C, and then cooled to 30 ° C to 35 ° C with paddle stirring.
[0024]
Example 11: Emulsion
Figure 2004231544
(Preparation method) Both the phase A component and the phase B component are heated and dissolved at 80 ° C., and the phase B component is gradually added to the phase A component while stirring with a homomixer, followed by stirring at 5000 rpm for 5 minutes. Cool with paddle agitation, add Phase C ingredients at about 50 ° C, cool to 35 ° C to 40 ° C with agitation.
[0025]
Example 12: Lotion
Figure 2004231544
(Preparation method)
The oil phase component and the aqueous phase component are also heated and dissolved at 50 ° C., and the oil phase component is gradually added to the aqueous phase component with stirring to solubilize. Cool to 30 ° C. with stirring.
[0026]
Example 13: Serum
Figure 2004231544
(Preparation method)
The phase A to D components are dissolved at room temperature. The B-phase component is gradually added to the A-phase component with stirring to make a viscous liquid, and then the C-phase component and the D-phase component are added to make the mixture homogeneous.
(Evaluation of whitening effect)
The experimental skin external preparations of Examples 1 to 6 and Comparative Examples 1 to 5 were applied to the faces of the test subjects (five women in the 20 to 40 years old, 25) twice a day in the morning and evening for three months. The whitening effect after one month, two months, and three months was examined by visual judgment, and the degree of darkness, spots, and freckles before and after the test was evaluated on a four-point scale.
(Evaluation criteria)
1: The effect of improving darkness, spots, and freckles was remarkably confirmed.
2: The effect of improving darkness, spots, and freckles was confirmed.
3: The effect of improving darkness, spots, and freckles was slightly confirmed.
4: There was no improvement effect of black and white, spots, and freckles.
(Judgment criteria)
:: 80% or more of the subjects showed an improvement of evaluation criteria 2 or more.
:: Improvement of evaluation criterion 2 or more was observed in 50% or more and less than 80% of subjects.
C: Improvement of about 3 in evaluation criteria was observed in 30% or more and less than 50% of subjects.
×: No improvement was observed.
[0027]
[Table 3]
Figure 2004231544
As shown in Table 3, the hydrogenated soybean phospholipid has a mild whitening effect, but shows a significant whitening effect in about three months.
[0028]
【The invention's effect】
As described in detail above, phospholipids such as glycerophospholipids and sphingolipids are components having a mild whitening effect, and hydrogenated soybean phospholipids are excellent in safety and are amphiphilic substances. It can be seen that this is an excellent whitening component that is easily used in cosmetics and the like.

Claims (4)

リン脂質、及び/又はリン脂質の水素添加物を必須成分とするメラニン生成抑制剤。A melanin production inhibitor comprising a phospholipid and / or a hydrogenated phospholipid as an essential component. リン脂質、及び/又はリン脂質の水素添加物が、グリセロリン脂質、スフィンゴリン脂質である請求項1に記載のメラニン生成抑制剤。The melanin production inhibitor according to claim 1, wherein the phospholipid and / or a hydrogenated phospholipid are glycerophospholipid and sphingolipid. リン脂質が、水素添加大豆リン脂質である請求項1に記載のメラニン生成抑制剤。The melanin production inhibitor according to claim 1, wherein the phospholipid is hydrogenated soybean phospholipid. 請求項1〜3に記載のリン脂質をメラニン生成抑制剤として用いる化粧料、及び皮膚外用剤。A cosmetic and an external preparation for skin using the phospholipid according to claim 1 as a melanin production inhibitor.
JP2003020321A 2003-01-29 2003-01-29 Utilization of phospholipid as melamine production inhibitor Pending JP2004231544A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003020321A JP2004231544A (en) 2003-01-29 2003-01-29 Utilization of phospholipid as melamine production inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003020321A JP2004231544A (en) 2003-01-29 2003-01-29 Utilization of phospholipid as melamine production inhibitor

Publications (1)

Publication Number Publication Date
JP2004231544A true JP2004231544A (en) 2004-08-19

Family

ID=32949985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003020321A Pending JP2004231544A (en) 2003-01-29 2003-01-29 Utilization of phospholipid as melamine production inhibitor

Country Status (1)

Country Link
JP (1) JP2004231544A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005320285A (en) * 2004-05-10 2005-11-17 Kose Corp Gel-like cosmetic
WO2007034927A1 (en) * 2005-09-22 2007-03-29 Snow Brand Milk Products Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
JP2007112793A (en) * 2005-09-22 2007-05-10 Snow Brand Milk Prod Co Ltd Sphingomyelin-containing medicine, food and drink or fodder
JP2009203191A (en) * 2008-02-28 2009-09-10 Kose Corp Skin-whitening agent and skin-whitening preparation for external use
KR101155416B1 (en) * 2010-02-17 2012-06-14 주식회사 케이티앤지생명과학 Composition for reducing the exudation of serum proteins
JP2012167104A (en) * 2005-09-22 2012-09-06 Snow Brand Milk Products Co Ltd Sphingomyelin-containing medicine
US8853195B2 (en) 2005-02-28 2014-10-07 Kt & G Corporation Composition for reducing the exudation of serum proteins
JP2019064962A (en) * 2017-10-02 2019-04-25 ロレアル Composition comprising ellagic acid compound
WO2020137017A1 (en) * 2018-12-26 2020-07-02 日本精化株式会社 Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation mitigator, wrinkle-ameliorating agent, complex, cosmetic and external preparation for skin
JP2020105076A (en) * 2018-12-26 2020-07-09 日本精化株式会社 Phosphatidylinositol-containing bioactive composition

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005320285A (en) * 2004-05-10 2005-11-17 Kose Corp Gel-like cosmetic
US8853195B2 (en) 2005-02-28 2014-10-07 Kt & G Corporation Composition for reducing the exudation of serum proteins
US9186366B2 (en) 2005-09-22 2015-11-17 Megmilk Snow Brand Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
WO2007034927A1 (en) * 2005-09-22 2007-03-29 Snow Brand Milk Products Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
JP2007112793A (en) * 2005-09-22 2007-05-10 Snow Brand Milk Prod Co Ltd Sphingomyelin-containing medicine, food and drink or fodder
AU2006293026B2 (en) * 2005-09-22 2012-08-16 Megmilk Snow Brand Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
JP2012167104A (en) * 2005-09-22 2012-09-06 Snow Brand Milk Products Co Ltd Sphingomyelin-containing medicine
US8486916B2 (en) 2005-09-22 2013-07-16 Megmilk Snow Brand Co., Ltd. Medicine, food and drink or feed containing sphingomyelin
JP2009203191A (en) * 2008-02-28 2009-09-10 Kose Corp Skin-whitening agent and skin-whitening preparation for external use
KR101155416B1 (en) * 2010-02-17 2012-06-14 주식회사 케이티앤지생명과학 Composition for reducing the exudation of serum proteins
JP2019064962A (en) * 2017-10-02 2019-04-25 ロレアル Composition comprising ellagic acid compound
JP7063567B2 (en) 2017-10-02 2022-05-09 ロレアル Composition containing ellagic acid compound
WO2020137017A1 (en) * 2018-12-26 2020-07-02 日本精化株式会社 Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation mitigator, wrinkle-ameliorating agent, complex, cosmetic and external preparation for skin
JP2020105076A (en) * 2018-12-26 2020-07-09 日本精化株式会社 Phosphatidylinositol-containing bioactive composition
CN113226277A (en) * 2018-12-26 2021-08-06 日本精化株式会社 Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation
JP7178257B2 (en) 2018-12-26 2022-11-25 日本精化株式会社 Bioactive composition containing phosphatidylinositol
CN113226277B (en) * 2018-12-26 2023-12-01 日本精化株式会社 Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation

Similar Documents

Publication Publication Date Title
EP2088986B1 (en) Skin external preparation in the form of water-in-oil emulsion comprising ceramide
JP2007077066A (en) Parakeratosis inhibitor and pore-contracting agent
JP2004231544A (en) Utilization of phospholipid as melamine production inhibitor
JP3908126B2 (en) Epidermal keratinization normalizing agent and skin external preparation containing the same
KR100824212B1 (en) Composition for skin protection containing placenta and preparation method thereof
JP5546809B2 (en) Emulsified cosmetics
JP2012001467A (en) Skin external preparation
JP6356457B2 (en) Ceramide-containing external preparation composition
JP5000033B2 (en) Advanced hydrogenated lecithin
JP6859428B2 (en) TRPA1 activity inhibitor
JP2004131401A (en) Skin cosmetic
JP4887050B2 (en) Inadequate keratinization inhibitor, pore reducing agent
JP2015166330A (en) cosmetic
JP4630102B2 (en) Hyaluronic acid production promoter and cosmetics containing the same
JP2018177757A (en) Cosmetic
JP2016150916A (en) Sebum secretion inhibitor
JPH06321754A (en) Skin beautifying agent
JP2000344697A (en) Long-chain branched alcohol and cosmetic and external preparation produced by using the alcohol
JPH0665053A (en) External preparation for skin
JP2000169339A (en) Cosmetic having beautifully whitening effect
JP2000204019A (en) Makeup cosmetic having bleaching effect
KR20090022902A (en) Cosmetic composition for moisturization containing amino acids from yeast, betain, taurine and inositol
JP3853097B2 (en) Topical skin preparation
JPH08283137A (en) Skin lightening cosmetic
JP2022549751A (en) Cosmetic composition containing 5-benzylaminosalicylic acid derivative and method of topical use thereof